<DOC>
	<DOCNO>NCT02927717</DOCNO>
	<brief_summary>Study purpose evaluate baseline clinical data , outcome front-line Rituximab contain chemotherapy survival patient grade 3b Follicular Lymphoma . Also histological central review plan order re-assess baseline diagnosis accord new 2016 World Health Organization ( WHO ) criterion .</brief_summary>
	<brief_title>An Italian Experience Grade 3b Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>Diagnosis grade 3b Follicular Lymphoma Age &gt; 18 year Frontline treatment Rituximab contain chemotherapy Availability histological sample central review Other lymphoma diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Grade 3b Follicular Lymphoma</keyword>
	<keyword>2016 WHO Criteria</keyword>
	<keyword>Front-line treatment</keyword>
	<keyword>Rituximab</keyword>
</DOC>